Skip to content

Anthony Lozama

5 papers in the library · 98 citations · publishing 2009-2013

Papers

Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.

Journal of natural products April 25, 2011 Anthony Lozama, Christopher W Cunningham, Michael J Caspers et al. 40 citations

New chemical methods using microwave heating enabled the first successful Diels-Alder cycloaddition reactions on the furan ring of salvinorin A, a neoclerodane diterpene natural product. This approach introduced electron-withdrawing groups and bulky aromatic rings at the C-12 position. Some of the resulting cycloadducts, specifically dimethyl- and diethylcarboxylate analogues, retained affinity and selectivity for kappa opioid receptors and acted as full agonists. However, converting these cycloadducts into planar phenyl ring systems reduced their receptor affinity. The work provides a novel strategy for rapidly exploring structure-activity relationships of furan-containing natural products.

Semisynthetic neoclerodanes as kappa opioid receptor probes.

Bioorganic & medicinal chemistry May 1, 2012 Kimberly M Lovell, Tamara Vasiljevik, Juan J Araya et al. 35 citations

A palladium-catalyzed cross-coupling reaction (Liebeskind-Srogl) applied to a modified natural product scaffold produces ketone analogs of salvinorin A at neutral pH and room temperature, expanding synthetic access to this class. A one-step microwave method converts salvinorin A to its 12-epimer, previously requiring multiple steps. Several new analogs (alkene 9 and aromatic compounds 12, 19, 23, 25, 26) retain affinity and selectivity for kappa opioid receptors (KOP), and the furan-2-yl analog (31) shows similar affinity to the parent compound. These results indicate that diverse aromatic groups attached to the decalin core may be tolerated by KOP receptors, potentially yielding additional ligands.

Synthesis of neoclerodane diterpenes and their pharmacological effects.

Topics in current chemistry January 1, 2011 Kimberly M Lovell, Katherine M Prevatt-Smith, Anthony Lozama et al. 17 citations

Salvinorin A, a unique compound, stands out as the first opioid ligand discovered without a basic nitrogen, challenging traditional understanding. Researchers developed sophisticated synthetic methods to recreate and modify its complex structure, which features seven chiral centers. By focusing on specific structural changes, they successfully created new analogs. These efforts yielded promising compounds with diverse and interesting biological activities, highlighting the power of chemical synthesis in drug discovery.

LC-MS/MS quantification of salvinorin A from biological fluids.

Analytical methods : advancing methods and applications December 21, 2013 Michael J Caspers, Todd D Williams, Kimberly M Lovell et al. 6 citations

A method using liquid chromatography-tandem mass spectrometry (LC-MS/MS) measures the hallucinogen salvinorin A in non-human primate cerebrospinal fluid (CSF) and human plasma. For CSF, simple dilution with acetonitrile and formic acid replaces solid phase extraction. Human plasma requires centrifugation, then loading onto a C18 SPE column. A shallow acetonitrile/water gradient elutes the compound. Limits of quantification are 0.0125 ng/mL for CSF and 0.05 ng/mL for plasma. Interday precision and accuracy are below 1.7% and 9.42% for CSF and 3.47% and 12.37% for plasma. The method determined salvinorin A concentrations in a Rhesus monkey study and a human trial using behaviorally active doses.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Organic & biomolecular chemistry September 21, 2009 Denise S Simpson, Kimberly M Lovell, Anthony Lozama et al.

Modifying the furan ring of salvinorin A, the active component of Salvia divinorum, produced new compounds with activity at opioid receptors. A computational study predicted salvinorin A to be a reproductive toxicant in mammals, suggesting its use may have adverse effects. Two new compounds, piperidine 21 and thiomorpholine 23, were identified as selective partial agonists at kappa opioid receptors. This suggests further structural changes could yield ligands with good opioid receptor selectivity but lower toxicity.